flurbiprofen and rivastigmine

flurbiprofen has been researched along with rivastigmine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z	1
Mathew, B	1

Reviews

2 review(s) available for flurbiprofen and rivastigmine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment. Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:9 Topics: Acetylcholinesterase; Alzheimer Disease; Chalcones; Drug Approval; Drug Design; Enzyme Inhibitors; Flurbiprofen; Humans; Monoamine Oxidase; Neuroprotective Agents; Rivastigmine; Structure-Activity Relationship; United States; United States Food and Drug Administration	2020

Article

Year

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment.

Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:9

Topics: Acetylcholinesterase; Alzheimer Disease; Chalcones; Drug Approval; Drug Design; Enzyme Inhibitors; Flurbiprofen; Humans; Monoamine Oxidase; Neuroprotective Agents; Rivastigmine; Structure-Activity Relationship; United States; United States Food and Drug Administration

2020

Other Studies

2 other study(ies) available for flurbiprofen and rivastigmine

Article	Year
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease. Bioorganic & medicinal chemistry, 2018, 12-15, Volume: 26, Issue:23-24 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship	2018

Article

Year

Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.

Pharmaceutical research, 2014, Volume: 31, Issue:4

Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014

Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.

Bioorganic & medicinal chemistry, 2018, 12-15, Volume: 26, Issue:23-24

Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship

2018